Vinva Investment Management Ltd Purchases 4,909 Shares of Amgen Inc. (NASDAQ:AMGN)

Vinva Investment Management Ltd boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 22.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 26,522 shares of the medical research company’s stock after acquiring an additional 4,909 shares during the period. Vinva Investment Management Ltd’s holdings in Amgen were worth $6,877,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. Swedbank AB raised its stake in Amgen by 1.1% during the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock worth $173,639,000 after acquiring an additional 5,751 shares during the period. Quest Partners LLC grew its holdings in Amgen by 1,568.7% during the 3rd quarter. Quest Partners LLC now owns 1,919 shares of the medical research company’s stock valued at $618,000 after buying an additional 1,804 shares in the last quarter. Joseph Group Capital Management grew its holdings in Amgen by 15.7% during the 3rd quarter. Joseph Group Capital Management now owns 8,633 shares of the medical research company’s stock valued at $2,782,000 after buying an additional 1,169 shares in the last quarter. Pathstone Holdings LLC grew its holdings in Amgen by 1.7% during the 3rd quarter. Pathstone Holdings LLC now owns 98,605 shares of the medical research company’s stock valued at $31,772,000 after buying an additional 1,694 shares in the last quarter. Finally, Caprock Group LLC grew its holdings in Amgen by 6.6% during the 3rd quarter. Caprock Group LLC now owns 16,424 shares of the medical research company’s stock valued at $5,292,000 after buying an additional 1,017 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 0.5 %

NASDAQ AMGN opened at $318.65 on Wednesday. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company has a fifty day moving average of $294.12 and a two-hundred day moving average of $298.91. The firm has a market capitalization of $171.18 billion, a price-to-earnings ratio of 42.21, a PEG ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 2.99%. Amgen’s dividend payout ratio (DPR) is 126.09%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of research analyst reports. Redburn Partners cut their price objective on shares of Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Piper Sandler Companies reaffirmed an “overweight” rating and set a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Finally, Truist Financial cut their target price on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a report on Wednesday, January 8th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus price target of $314.04.

Insider Transactions at Amgen

In other news, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares in the company, valued at approximately $11,240,533.68. This trade represents a 40.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is currently owned by insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.